GO28398 (vemurafenib + phenprocoumon)


Protocolnummer:
Gesloten

Ziekenhuizen:
GO28398 (vemurafenib + phenprocoumon)

Titel:
A phase 1 , open-label, multicenter, randomized, paralell study to investigate the effect of Vemurafenib on the pharmacokintetics of a single oral dose of phenprocoumon in patients with BRAFV600 mutation - positive metastatic malignancy.

Behandeling:
Single dose of phenprocoumon on day 1 of day 22 (randomized) and vemurafenib 960mg bid on day 1-29

Stadium:
Stadium irresectable IIIc/IV

Belangrijkste in/exclusiecriteria:
In: 18-70 years, ECOG of 0-2, adequate hematologic and end organ function, Ex: prior treatment with vemurafenib within 42 days, cardiac or pulmonary dysfunction, bleeding or coagulation disorders, liver disease - or active HEP B or C infection, HIV infection , history of myocardial infarction within 6 months.

Contactpersoon:

Alle trials